Ohio born & raised, now loving Dallas! Medical Device Space for 25 years. Love of Family, Friends, Work, Soccer, Cycling, Running, and enjoying the Outdoors!
Dallas, TX
Joined May 2015
- Tweets1.2K
- Following223
- Followers219
- Likes1.7K
Roger Owens retweeted
What does bringing AI into clinical practice look like?
Explore real-world evaluations and hear from clinicians using EchoGo® in practice—from implementation experiences to perspectives on how its insights help inform further evaluation and patient management.
Explore here: hubs.la/Q04BrjRt0
#HFpEF #CardiacAmyloidosis #ATTRCM #ClinicalAI
Roger Owens retweeted
🚨Now available on YouTube- Hidden in Plain Sight: Earlier Detection of HFpEF and Cardiac Amyloidosis to Improve AF Ablation and LAAC Outcomes
Hear from Ultromics Chief Commercial Officer @rogerrowens and leading experts in electrophysiology as they discuss earlier recognition, implications for patient management, and what it takes to integrate AI into clinical workflows.
Watch the full roundtable: hubs.la/Q04B4kJz0
#HRX2026 #AFib #HFpEF #CardiacAmyloidosis
Roger Owens retweeted
A BIG thank you to our supporters who, for the 11th time in program history, helped produce another sellout at Mustang Memorial Field Friday! The largest NCAA men's soccer crowd of the season!
📰➡️gopoly.com/news/2026/9/25/me…
Thank you to Drs. Bunch, Kowal , Baykaner, Akoum and Michaelfor the thoughtful discussion during this roundtable.
Last week at HRX, our roundtable explored how earlier identification of HFpEF and cardiac amyloidosis could inform care for patients undergoing AF ablation and LAAC—and how EchoGo® may support earlier consideration of these conditions through routine echocardiography.
Thank you to everyone who shared their perspectives and made it such a thoughtful conversation. We’re also grateful to @experienceHRX for bringing us together for a great meeting!
Panelists: Michael Raccuglia JR., @rogerrowens, Robert Kowal, @TinaBaykaner45, @NazemAkoum, @TJaredBunch
Roger Owens retweeted
Ultromics is headed to Phoenix for #HFSA2026!
We’re looking forward to supporting the meeting and connecting with attendees to share how Ultromics’ clinically validated AI can fit into existing workflows to support earlier detection of HFpEF and Cardiac Amyloidosis.
#HFSA #HFpEF #ATTRCM #Amyloid #ClinicalAI
Roger Owens retweeted
HFpEF and cardiac amyloidosis frequently hide behind a presentation of atrial fibrillation. If these conditions were identified earlier—before AF ablation or left atrial appendage closure—could those insights lead to more informed procedural decisions and better outcomes for patients?
Join Ultromics CCO @rogerrowens and a panel of leading electrophysiology experts this Saturday at HRX as they explore this question and discuss the potential of earlier identification using Ultromics’ FDA-cleared EchoGo® platform.
🗓️ Saturday, September 19 | 10:45–11:30 a.m. EDT
🔗 hubs.la/Q04xNSdh0
Looking forward to this roundtable at HRX and thank you I. Advance to our panel of physicians
Patients presenting with atrial fibrillation may also be living with undetected HFpEF or cardiac amyloidosis. Could identifying these conditions earlier help inform decisions surrounding AF ablation and LAAC?
Join Ultromics Chief Commercial Officer @rogerrowens and leading experts in electrophysiology at HRX Live for Hidden in Plain Sight: Earlier Detection of HFpEF and Cardiac Amyloidosis to Improve AF Ablation and LAAC Outcomes to learn more.
September 19, 2026
10:45–11:30 a.m. EDT
🔗 hubs.la/Q04wZP260
Roger Owens retweeted
Patients presenting with atrial fibrillation may also be living with undetected HFpEF or cardiac amyloidosis. Could identifying these conditions earlier help inform decisions surrounding AF ablation and LAAC?
Join Ultromics Chief Commercial Officer @rogerrowens and leading experts in electrophysiology at HRX Live for Hidden in Plain Sight: Earlier Detection of HFpEF and Cardiac Amyloidosis to Improve AF Ablation and LAAC Outcomes to learn more.
September 19, 2026
10:45–11:30 a.m. EDT
🔗 hubs.la/Q04wZP260
Roger Owens retweeted
Cardiac amyloidosis remains widely underdiagnosed, leaving many patients without answers or access to appropriate care.
EchoGo® Amyloidosis has been validated across diverse patient populations, demonstrating consistent performance in identifying signs of cardiac amyloidosis—even across challenging clinical subgroups. Using a single apical four-chamber view from a routine echocardiogram, it augments physician evaluation and may help connect patients to the appropriate care pathway sooner.
#CardiacAmyloid #ATTRCM #Amyloid #Echocardiography
Roger Owens retweeted
Cardiac amyloidosis remains underdiagnosed, with many patients experiencing significant delays before receiving a diagnosis. Among patients with HFpEF, studies have found an underlying prevalence of cardiac amyloidosis—highlighting an important opportunity for earlier clinical consideration.
EchoGo® supports the detection of complex cardiac diseases, including HFpEF and cardiac amyloidosis. Learn more at hubs.la/Q04vCS3Y0
#HFpEF #ATTRCM #Amyloid #Echocardiography
Roger Owens retweeted
EchoGo® works within existing echo workflows, using secure, scalable cloud infrastructure to support a streamlined process from image analysis and report delivery through billing. Designed for real-world clinical practice, the platform integrates with existing hospital systems to deliver AI-driven insights without adding unnecessary steps.
Schedule a demo to see how EchoGo® can impact your health system!
🔗hubs.la/Q04vCZLS0
Roger Owens retweeted
Up to 64% of HFpEF cases go undiagnosed. A large share of the rest come back indeterminate. EchoGo® Heart Failure is built to close that gap from a routine echo, with no change to how studies are scanned, read or reported.
🔗 hubs.la/Q04vtrZt0
#HFpEF #Echocardiography #AIinCardiology #HeartFailure
Roger Owens retweeted
By supporting earlier identification through routine echocardiography, EchoGo® Heart Failure may help connect patients to appropriate evaluation and care sooner.
An independent impact analysis from the American Heart Association AI Assessment Lab, powered by Dandelion Health, found that HFpEF detection using EchoGo® Heart Failure may lead to 564 fewer emergency department visits per 10,000 patients over five years.
🔗 hubs.la/Q04vcKc40
#HFpEF #Echocardiography #Cardiology #HealthcareAI
Roger Owens retweeted
Join Ultromics Chief Commercial Officer @rogerrowens at HRX Live for Hidden in Plain Sight: Earlier Detection of HFpEF and Cardiac Amyloidosis to Improve AF Ablation and LAAC Outcomes.
Alongside leading experts in electrophysiology, Roger will explore how the potential for earlier identification with EchoGo® Heart Failure and EchoGo® Amyloidosis could inform patient selection, pre-procedure management, procedural planning, and anticoagulation strategies for AF ablation and LAAC.
September 19, 2026
10:45–11:30 a.m. EDT
🔗 experiencehrx.com/event/hidd…
The best ideas don't happen in silos.
They happen when diverse voices come together to ask better questions, challenge assumptions, and share what they're learning.
In less than a month, more than 30 roundtable discussions will unite these diverse voices for conversations ranging from AI and remote monitoring to workflow transformation and breakthrough innovations.
▶️ Join the conversations shaping what's next at HRX Live 2026: experiencehrx.com/hrx-live/?…
HRX Live 2026 | September 18-20, 2026 | Signia by Hilton Atlanta
An @HRSonline Experience
HRX Live 2026 Production Team: @JonPicciniSr @PrashSanders @TinaBaykaner45 @brynndechert30 @MehakDhande @DavidDuncker @J_Hendriks1 @jasoncjacobson @RCKowalMD @Dominik_Linz Mike Lloyd, Olivier Manfredi, @drsuneet @Drdevignair
@jenniferavari @ba_steinberg @EmmaSvennberg @KTamirisaMD @NTrayanova @leftbundle
#Xplorers2026 #HRXLive #HRX2026 #Electrophysiology #CardiologyInnovation #MedTech #DigitalHealth #AIinHealthcare #EPeeps #HRXLive2026 @AccurKardia @VoltaMedical @Philips_AMD @SiemensHealth @WearLinq @ultromics
Roger Owens retweeted
Earlier identification using EchoGo® Heart Failure may create value for both patients and health systems. In an AHA AI Assessment Lab modeled cohort of 10,000 patients over 5 years, earlier identification and intervention were projected to save ~$1,812 per patient.
Learn more at hubs.la/Q04tqMtr0
#HFpEF #CardiacAI #Echocardiography #HealthcareAI
Roger Owens retweeted
🫀 Dual-disease detection from a single apical four-chamber view.
Schedule a demo with a local representative at ultromics.com to learn how EchoGo® can support earlier disease identification within your existing echocardiography workflow.
Roger Owens retweeted
Nearly 1 in 5 patients hospitalized with acute decompensated HFpEF are readmitted within 30 days.¹
This downstream burden highlights the opportunity to identify HFpEF earlier. According to modeling from the American Heart Association AI Assessment Lab, EchoGo® Heart Failure may support earlier identification—potentially leading to fewer hospitalizations and readmissions.²
Learn more at ultromics.com/press-releases…
¹ DeAngelo S, et al. Int J Heart Fail. 2025;7(1):21–29.
² American Heart Association AI Assessment Lab, powered by Dandelion Health. EchoGo® Heart Failure Impact Analysis Report. 2026.
Roger Owens retweeted
Earlier identification can create an opportunity for earlier action.
The AHA AI Assessment Lab found EchoGo® Heart Failure could identify HFpEF up to 263 days earlier than standard practice. Designed for existing echo workflows, EchoGo® helps bring AI-supported insights into clinical practice.
#HFpEF #HeartFailure #ClinicalAI #Echocardiography
Roger Owens retweeted
Designed to fit the way echocardiography teams already work. EchoGo® integrates with existing echo workflows through secure, scalable cloud infrastructure—supporting a streamlined process from image analysis and report delivery through billing.
Clinical AI built for implementation in everyday care. Learn more at ultromics.com.
#ClinicalAI #Echocardiography #HeartFailure #HealthcareInnovation